Preferential incorporation of sangivamycin into ribonucleic acid in Sarcoma 180 cells in vitro.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000378:metabolism*; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000096:biosynthesis; D051379:Mice; D011741:Pyrimidine Nucleosides / Q000378:metabolism*; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D012510:Sarcoma 180 / Q000378:metabolism*; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D004273:DNA, Neoplasm; D011741:Pyrimidine Nucleosides; D012334:RNA, Neoplasm; C005699:sangivamycin